{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"description":"Summary statistics will be used for CR. Responses will be evaluated by the International Uniform Response Criteria for Multiple Myeloma.","groups":[{"description":"All Study Participants","id":"OG000","title":"All Study Participants"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Dose Level 7; Bendamustine 90mg/m2, ABT-888 400mg BID Participants treated on Dose Level 7 make up the cohort expansion of VBR in participants with CD20+ B-cell lymphoma.","reportingStatus":"POSTED","timeFrame":"2 years","title":"Complete Response (CR) to Study Treatment (Phase IIa)","type":"SECONDARY","unitOfMeasure":"Participants"}